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Abstract 
The human immunodeficiency virus type 1 (HIV-1) remains a global health threat and is increasingly 
becoming a female epidemic due to gender inequalities.  The introduction of antiretroviral therapy (ART) 
has greatly increased the life span while reducing AIDS-related deaths in HIV-1-infected people. 
However, some patients experience adverse effects during ART due to an acute inflammatory response 
termed immune reconstitution inflammatory syndrome (IRIS), which is a paradoxical clinical worsening 
upon initiation of ART that is thought to be due to a hyperactive or uncontrolled immune restoration. 
Studies have shown that females infected with HIV-1 elicit a stronger immune response and faster disease 
progression compared to men with the same viral load. Given the above mentioned higher baseline levels 
of immune activation in HIV-1 infected females, we hypothesized that immune restoration during ART 
will have significant sex-based differential outcomes.   
The aim of this project was to understand the impact of immune reconstitution in HIV-1-infected men and 
women during ART by investigating antigen presenting cells (monocytes, myeloid dendritic cells (mDCs) 
and plasmacytoid dendritic (pDCs) cells) phenotype and function. In total, we investigated cryopreserved 
samples from eleven HIV-1-infected males and thirteen HIV-1-infected females from which peripheral 
blood mononuclear cells (PBMCs) and plasma samples were longitudinally collected at defined time 
points, including before the initiation of ART (TP01), after 1-4 months (TP02) and after 5-8 months of 
treatment initiation. Changes in toll-like receptor (TLR) responsiveness were analyzed following 
stimulation with the following toll-like receptor (TLR) ligands: TLR4 ligand Lipopolysaccharide, TLR7/8 
ligand CL097, and the TLR9 ligand ODN2216/ CpG. Multiparameter flow cytometry was used to analyze 
the cytokine production upon TLR stimulation as well as the level of immune activation by analyzing 
phenotypic characteristics of antigen-presenting cells including monocytes subsets. In addition, multiplex 
analysis was used to determine levels of plasma pro-inflammatory cytokines (IFN-ɣ, IFN-α, IL-1β, IL-4, 
IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, TNF-α, IL-12p70, GM-CSF, MIP-1β and IP-10), in males and 
females at all time-points. 
Our results show that the expression of immune activation markers (measured by HLA-DR+ and CD38+ 
on T cells) did not significantly differ between males and females, although females showed elevated 
levels of both activated CD8+ and CD4+ T cells at baseline, the activation levels decreased upon ART 
initiation. Furthermore, our results demonstrated an increase in the proportion of classical monocytes 
(CD14++CD16-) in females compared to males at baseline (p=0.03). We did not observe any significant 
differences in the percentage of intermediate (CD14++CD16+) and non-classical monocytes 
(CD14+CD16++) between males and females at any time point analyzed. Similarly, no sex differences 
xi 
 
were evident after TLR ligand stimulation on monocytes in terms of cytokines measured (IFN-α, TNF-α, 
MIP-1β and IL-12). Interestingly, upon TLR9 stimulation, a significantly higher percentage of pDCs from 
females produced IFN-α (p=0.001, TP03), MIP-1β (p=0.001, at TP02) and TNF-α (p˂0.01, p˂0.001, 
TP02 and TP03 respectively) during ART compared to males. In addition, females had increased IFN-α 
(p=0.01) and TNF-α (p=0.004) production on pDCs during ART compared to baseline following TLR9 
stimulation.  
Taken together, our data suggest sex-specific differences in the level of immune reconstitution during 
ART, as females show signs of elevated immune response and inflammation compared to males 
Therefore, these findings may provide a basis for future studies in larger cohorts aimed at adapting ART 
therapy based on sex differences in disease progression rates in men and women.  
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CHAPTER ONE: LITERATURE REVIEW 
1.1 Global overview of the HIV epidemic vs. South Africa 
The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency 
syndrome (AIDS) which was initially oberseved in 1981 in homosexual men who presented with 
depletion of T-lymphocytes and opportunistic infection (Friedman-Kien et al., 1981). HIV has since been 
described as one of the world’s leading health challenges and is considered the leading global infectious 
killer with 39 million estimated deaths reported since the 1980s. It has been reported that 1.1 million 
people have died as a result of AIDS-related diseases in 2015 (UNAIDS, 2016). According to the World 
Health Organization (WHO), approximately 36.9 million people were living with HIV/AIDS worldwide 
despite having the number of new infections declining from 4.8 million in 2004 to 2.1 million in 2016 
(UNAIDS, 2016). Moreover, Sub-Saharan Africa is the epicenter of the epidemic, with 25.8 million 
people living with HIV-1 in 2014, followed by Asia with 5 million HIV infections. Middle East and 
North Africa had the least cases of HIV-1 infections at approximately 240,000 (Figure1.1). 
Even though new infections have declined, South Africa continues to have the highest prevalence of HIV-
1 compared to other countries in the world, where 7 million people are reported to be infected by the 
virus. Furthermore, 380,000 new infections were reported in 2016 and in the same period 200,000 people 
have been reported to have died of AIDS related illnesses (Zuma et al., 2016). The prevalence of HIV 
disease differs by geographical region and is reported to be higher in rural informal areas than in urban 
areas. The KwaZulu-Natal (KZN) province has the highest HIV-1 infection prevalence (16.9%), closely 
followed by Mpumalanga (14.1%), Free State (14%) and North West (13.3%) provinces, respectively. 
The Western Cape had the lowest HIV-1 prevalence (5%) followed by the Northern Cape (7.4%) and 
Limpopo (9.2%) (Simbayi et al., 2014). Although KZN has the highest HIV-1 prevalence, this province 
has achieved notable reductions in mother to child transmission (MTCT), decreasing from 9.6% in 2008 
to less than 2.0% at the end of 2014 (AVERT, 2017). 
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Figure 1.1: Global view of children and adults living with HIV in 2014. Sub-Saharan Africa experiences the 
great burden of HIV (UNAIDS, 2016). 
1.1.1 Sex differences in HIV-1 infection in South Africa  
The epidemic continues to have a profound effect on women accounting for 60% of people infected with 
HIV-1, particularly young women, since they represent a vulnerable population due to factors such as  
sexual violence, limited economic opportunities, sex with older men and inability to negotiate condom 
usage. As a result,  of these factors, HIV-related risks have become acute for young girls and women in 
South Africa (HIV/AIDS, 2015). The prevalence of HIV-1 was particularly highest among females aged 
30–34 and among males aged 35–49 (Figure 1.2). Moreover, the prevalence of HIV remains 
significantly higher in females than males in all age groups but remains highest at age 20-44. This shows 
a 10% difference between the sexes which highlights that the burden of the epidemic is mainly seen 
among females (Simbayi et al., 2014). 
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Figure 1.2: Overall HIV prevalence in gender of all age groups in South Africa. In all age groups females have 
high prevalence of HIV (Simbayi et al., 2014). 
 
1.3 Molecular Biology of HIV 
1.3.1 Structure of the HIV 
HIV is a Lentivirus of the Retroviridae family and it is surrounded by a lipid bilayer membrane derived 
from the human host cell. Each viral particle consists of glycoprotein complexes (gp41 trans-membrane 
protein and gp120 on the surface) that are anchored into the lipid membrane (Figure 1.3). The matrix 
protein p17 reside on the inner surface of the viral membrane, following this is the capsid protein (p24) on 
the core of viral particle, the capsid encloses two copies of (+) single stranded HIV-1 RNA which is the 
part of protein nucleic complex that consists of p7, reverse transcriptase (RT) and other crucial viral 
enzymes and proteins (Goto et al., 1998). 
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Figure 1.3: Structure of HIV virion particle. The capsid is surrounded by lipid membrane. HIV viral particles 
have diameter of 100nm and each viral particle contains 72 glycoprotein spikes which are embedded into the lipid 
membrane (Musumeci et al., 2015). 
 
The HIV genome is 9.2kb long with a long terminal repeat (LTR) at each end of its genome and consists 
of nine open reading frames (ORF) that produce viral proteins which are divided into 3 classes: 1) the 
structural proteins, including Gag, Pol and Env which are essential for structural formation and 
replication, 2) the regulatory proteins Tat and Rev which accelerate production of the HIV virus and 3) 
the accessory proteins Vpu, Vpr, Vif, and Nef ensure virus survival and transmission (see Figure 1.4) 
(Frankel and Young, 1998).  
Gag proteins are first synthesised as a polyprotein precursor p55, upon budding of the viral particle from 
the infected cell, p55 is cleaved by protease into four smaller matrix p17 proteins, which provide stability 
to the virion (Freed, 1998). The p24 capsid protein plays a crucial role in assembling of an infectious 
virus particle. Nucleocapsid is located at the virion core where it is tightly bound to RNA (Levin et al., 
2010). These proteins can be generated from Gag polyprotein or Gag-Pol precursor polyprotein which is 
generated through ribosomal frame shift (Könnyű et al., 2013).  
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The pol gene encodes for the polyprotein which is cleaved by protease to produce viral enzymes, namely, 
protease, integrase, reverse transcriptase and RNase H. Reverse transcriptase facilitates the translation of 
HIV ssRNA into dsDNA, which can then be integrated into human genome (provirus) by integrase.  
Protease cleaves both Gag and Gag-Pol polyprotein to create mature protein component of an infectious 
HIV virion. The env gene encodes a single protein gp160, which is normally cleaved into gp120 surface 
subunit and trans membrane gp41 glycoprotein by cellular enzymes (Schwartz and Nair, 1999). In 
addition, there are 2 regulatory genes and 4 accessory genes which are flanked at the 5’ to 3’ end region 
that codes for the proteins that modulate HIV’s ability to infect cells, replicate or cause disease 
(virulence) (Freed, 1998).   
 
Figure 1.4: The HIV-1 genome. Schematic representation of the HIV-1 gene products encoded by the HIV-1 
genomic sequence (Ayinde et al., 2010). 
 
1.3.2 HIV-1 replication 
HIV-1 infection takes place when the glycoprotein gp120 binds to the CD4 receptor and co-receptor 
chemokine receptor 5 (CCR5) or chemokine receptor type 4 (CXCR4) on the surface of the targeted cell.  
This interaction triggers conformational change in gp120 causing fusion of the viral and cellular 
membrane, permitting uncoating and release of the viral nucleic component into the cytoplasm of the host 
cell. Following fusion, the viral ssRNA is reverse transcribed into double stranded DNA by viral reverse 
transcriptase (RT) in the cytosol (Musumeci et al., 2015). Once synthesised, the viral DNA is transported 
to the nucleus as part of pre-integration complex (PIC). The viral DNA is inserted into the host DNA 
(provirus) inside the chromosomes by integrase. The provirus is transcribed using host’s RNA 
polymerase into messenger RNA (mRNA), these transcripts are then translated to viral protein outside the 
nucleus. The viral RNA and synthesised protein move towards the cell membrane and bud off as 
immature virus particles. The viral polyproteins are cleaved by protease to form infectious viral particles 
(Turner and Summers, 1999).  
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Figure 1.5: Schematic representation of the replication cycle (accessed from online material (MEDICINE, 2011).  
 
1.4 HIV Pathogenesis 
1.4.1 Clinical course of HIV-1 infection 
HIV is mostly transmitted through sexual intercourse, where the infection is established when a virion 
binds to CD4 T cells and co-receptors (CCR5 and CXCR4) at the mucosal surface. This is also mediated 
by dendritic cells at the surface of mucosa, where they bind the virus and migrate to lymphoid organ, 
mainly gut-associated lymphoid tissue (GALT) to present the virus to the susceptible T cells, thus causing 
systemic spread and triggering adaptive immune response (Fauci, 2007, Yuki et al., 2007). The course of 
untreated HIV infection can differ significantly amongst patients.  Different people progress at different 
rates through stages of HIV disease progression due to various factors such as genetic makeup among 
others. The course of HIV infection has been well documented and is characterized by an acute phase 
which usually last for a few weeks, followed by a chronic phase which last for 3-10 years and finally an 
AIDS phase which is caused by immune collapse (Figure 1.6). 
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Acute HIV-1 infection is characterized by an exponential increase in the viral RNA in the first three to six 
weeks, when infected individuals are highly infectious. At this stage of infection, there is no antibody 
formation but the viral RNA can be detected in serum and plasma. Dramatic changes take place in the 
immune system such as a rapid decline of CD4+ T cells and cytotoxic killing of infected cells by CD8+ T 
cells (Fauci et al., 1996). Following the acute phase, virus replication reaches a steady state called the 
viral set point, which takes place during the asymptomatic phase infection. As this stage comes to an end, 
the viral load increases and the CD4 count continues to steadily decrease thus resulting in full blown 
AIDS (Fanales-Belasio et al., 2010).  
The ability to control HIV replication and the rate of disease progression to AIDS is variable amongst 
individuals. A small percentage of individuals fall under the category of long-term non-progressors 
(LTNPs), these individuals infected with HIV maintain their CD4 count within the normal range for more 
than 7 years in the absence of ART. However, many individuals fall under the category of typical or rapid 
progressors. Following primary infection, these individuals progress to AIDS within 2 years to 10 years 
(Pantaleo and Fauci, 1996) .   
 
 
Figure 1.6: A course of HIV infection, depicting acquisition of HIV-1 infection up to the development of AIDS, 
the dynamics of the viral load in red and CD4 T cell in green is shown (An and Winkler, 2010).  
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1.5 The role of immune responses in the control of HIV 
The innate and adaptive responses both have significant roles in controlling HIV infection. Cells of the 
innate immune system such as natural killer (NK) cells, dendritic cells and macrophages are the first line 
of defence against HIV infection. NK cells plays a key role in controlling HIV-1 infection during early 
stages of infection and shape the adaptive immune response (Chakrabarti and Simon, 2010). They 
recognize and kill HIV-infected cells by direct recognition of viral proteins or virus induced stress ligands 
by activating NK cell receptors. HIV-1 infection results in up-regulated expression of stress ligands in 
infected cells or reduced expression of HLA class I molecules, thus causing infected cells to be more 
susceptible to NK cell-mediated lysis. Killing of HIV-1 infected cells by killer immunoglobulin receptors 
(KIR)+ NK cells is mediated by secretion of perforin and granzyme (Altfeld and Gale Jr, 2015). In 
addition, NK cells are involved in the clearance of infected cells by induction of antibody-dependent 
cellular cytotoxicity (ADCC), through the potent elimination of antibody-opsonized material via the 
activation of an Fc-receptor (FcR) on innate immune cells (Berger and Alter, 2011). 
Innate immune activation is accompanied by the induction and production of pro-inflammatory cytokines 
which subsequently leads to activated adaptive immune response, this includes B and T host cell mediated 
responses. T cells are the second subset of lymphocytes that mediate the adaptive immune response. CD8+ 
T cells, also referred to as cytotoxic T lymphocytes (CTL) plays an important role in antiviral immunity, 
they also have greater effect in controlling infection during acute HIV-1 infection (Perreau et al., 2013). 
HIV-specific T cell responses play an important role in decreasing viral load during acute infection as 
well as in being able to influence viral load set point. During primary infection, HIV-specific CD8+ T 
cells coincide with a decrease in viremia (Pantaleo and Fauci, 1996). One of the crucial role of HIV-
specific CD8+ T cells in controlling infection was demonstrated in macaques infected with SIV, where 
depletion of CD8+ T cells resulted in high Simian/Human Immunodeficiency (SHIV) viremia and disease 
progression (Saez-Cirion et al., 2014). Furthermore, studies have shown that protective HLA class I 
alleles mediate the initial CD8+ T cell response during acute HIV-1 infection (Chakrabarti and Simon, 
2010).  
CD4+ T cells, known as T helper' cells ensure crucial support to dendritic cells and B cells in order to 
induce HIV-specific CD8+ T cells and antibodies. Infection with HIV causes functional impairment of the 
immune system, subsequently resulting in immune deterioration (Chakrabarti and Simon, 2010). 
Regulatory CD4+ T cells (Tregs) accumulate in the gut during HIV-1 infection and might contribute to 
reduced pathogenesis by controlling chronic immune inflammation, and they could also exacerbate 
infection by suppressing the activation of effector T cells (Saez-Cirion et al., 2014).  
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HIV infection elicits an antibody or humoral response that targets HIV envelope protein anti-gp41 IgG 
and lack neutralizing activity during the early stages of infection (Saez-Cirion et al., 2014). Neutralizing 
antibodies with broad neutralizing activity that recognize conserved regions of the virus envelope protein 
are only generated after 2-3 years after infection in minority (20%) of individuals. However, the presence 
of these broadly neutralizing antibodies does not show efficacy in the control of viremia in vivo, but has 
been proven to strongly reduce viremia when administered to SIV-infected macaques and it was 
dependent on titer and quality of the antibody (Perreau et al., 2013). Studies have found IgA neutralizing 
antibodies in the genital tract of highly exposed seronegative females in different cohorts, indicating 
protection by these antibodies from AIDS acquisition in those subjects (Hirbod and Broliden, 2007). The 
potential role of non-neutralizing antibodies in the control of HIV-1 infection has been demonstrated. 
Non-neutralizing antibody achieve this by binding to infected cells and recruit activated effector cells 
(NK cells and macrophage), which induce cytolysis or apoptosis of infected cells.  This is accomplished 
by the formation of immune complex between the IgG Fab portion of the antibody with the viral protein 
on the cell surface and binding of the Fc portion to the Fc receptors (FcγRs) on effector cells which 
results in Antibody-dependent cellular cytotoxicity (ADCC) (Overbaugh and Morris, 2012). 
 
Figure 1.7: Innate and adaptive immune responses contributing to HIV-1 control (Walker and Xu, 2013).  
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1.6 Role of antigen presenting cells in HIV Pathogenesis 
Antigen-presenting cells (APCs) are important immune sentinels that recognize invading pathogens like 
HIV-1. They play a crucial role as a bridge between innate and adaptive immune systems as they 
constitute both adaptive and innate immune cells that mediate the cellular immune response by processing 
and presenting antigens to T cells and induce pro-inflammatory response against antigens (Nagy et al., 
2013). APCs of the innate immune system serve as the first line of defense against infection, they 
recognize and respond to infection using pattern recognition receptors, these receptors bind to ssRNA of 
HIV-1 and mediate immune response activation (Chang and Altfeld, 2010). Furthermore, classical APCs 
which include dendritic cells, macrophages and monocytes act as a reservoir of latent HIV infection that 
can possibly be resistant to antiretroviral therapy, however, this is still an area of debate (Chougnet et al., 
2002). 
1.6.1 Plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells (mDCs) 
Dendritic cells (DC) are cell population of strong antigen presenting cells derived from the bone marrow 
and are essential in initiating and regulating both innate and adaptive responses (Fauci et al., 1996). Two 
populations of DCs have been identified in blood, myeloid dendritic cells (mDCs) which are 
characterized as CD11c+ and plasmacytoid dendritic cells (pDCs) defined by CD123+. Myeloid dendritic 
cells (mDCs) are the most common DCs that are circulating in the blood while pDCs are present at low 
levels (0.1-1%). DCs respond to infection by recognizing pathogen-associated molecule patterns 
(PAMPs), HIV-1 ssRNA encodes for multiple PAMPs, which can be recognized by Toll-like receptors 
(TLRs) on the surface of mDCs and pDCs. As a result, DCs present HIV antigen to CD4+ T cells and 
induce immune responses (cytokine production). During chronic HIV infection, low counts of circulating 
DCs exist, and are only recovered by the initiation of antiretroviral therapy (Coleman and Wu, 2009). 
Plasmacytoid dendritic cells (pDCs) are the main natural IFN-α producers in vivo (Chakrabarti and 
Simon, 2010). Induction of IFN-α is one of the earliest antiviral defense mechanism which decreases 
HIV-1 infection of several cells and impairs HIV-1 transmission from dendritic cells (DC) to CD4+ T-
cells (Tavel et al., 2010). 
1.6.2 Monocytes 
Monocytes make up 3-8% of blood leukocytes in humans (Sassé et al., 2012), and they exhibit a 
significant immunological role during HIV-1 infection. This include, responding to inflammatory signals 
by moving to the site of infection where they will divide or differentiate into macrophages. Moreover, 
Monocytes play a vital role in presenting HIV antigen to T cells and they have also been suggested to 
serve as the reservoir of HIV-1 during highly active antiretroviral therapy (HAART), however, this topic 
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is still controversial (Spivak et al., 2011, Kandathil et al., 2016). Monocytes exist as three major subtypes 
characterized by CD14 and CD16 expression; classical monocytes (CD14++CD16-), intermediate 
(CD14++CD16+) and non-classical or inflammatory monocytes (CD14+CD16++). It has been reported that 
CD16 expressing monocytes exhibit great potential for HLA-restricted antigen presentation and pro-
inflammatory cytokine production (Zawada et al., 2011). The proportion of CD14+CD16++ and 
CD14++CD16+ are found in abundance in HIV-1 infection (Funderburg et al., 2012). As a result, there has 
been a great interest in CD14++CD16+ due to their co-expression of CCR5 which permits HIV infection. 
These cell subsets are capable of transferring HIV-1 infection across genital mucosal barrier as well as the 
central nervous system (Castley et al., 2014). 
1.6.3 Sensing of viral pathogens by APCs  
The APCs of the innate immune system play a significant role in sensing of viral pathogens and initiating 
antiviral immune responses. APCs sense viral pathogens through recognition of pathogen–associated 
molecular patterns (PAMPs) by pattern recognition receptors (PRRs), including toll-like receptors (TLRs) 
and RIG-1-like receptor (Nagy et al., 2013). Furthermore, several studies have  shown that two additional 
intracellular PRRs (interferon inducible protein I6 (IFI16) and cyclic GMP-AMP synthase (cGAS) sensed 
the HIV-1 infection by recognizing the viral reverse transcriptase product during the early stage of viral 
replication (Jakobsen et al., 2013, Li et al., 2013, Wu et al., 2013). Following pathogen recognition, rapid 
immune responses are initiated via signaling pathways, involving NFkβ, MyD88-IRF7 and mitogen-
activated protein kinase (MAPK), through phosphorylation of transcription factors which subsequently 
induce the production of pro-inflammatory cytokines such as IL-6, IL-12, and TNF-α and type I 
interferon is induced (Takeda and Akira, 2005). This inflammatory response to pathogens results in 
recruitment of both innate and adaptive immune cells to the site of infection (Nagy et al., 2013). 
One of the first events that takes place during interaction of APCs with an invading microorganisms is the 
engagement of cellular TLRs. TLRs are a family of pathogen sensors of innate immune system that 
trigger local inflammation, recruitment of effector cells, and secretion of cytokines that modulate both the 
innate and adaptive immune responses (Brichacek et al., 2010). These are membrane-bound receptors 
localized at the cellular or endosomal membranes, recognizing PAMPs via the leucine-rich repeat LRR 
domain and transducing signals to the intracellular environment through the Toll-interleukin-1 receptor 
TIR domain (Mogensen, 2009).  
TLR family members are expressed in wide variety of cells and have developed to recognize diverse 
range of pathogens. TLR pathways have been found to be involved in the persistent immune activation 
observed in chronically HIV-1– infected individuals (Chang and Altfeld, 2010). Furthermore, it has been 
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well established that HIV-1 encodes for multiple TLR7/8 ligands that mediate activation of the innate 
immune response (Mogensen, 2009). Additionally, TLR 3 and 9 have been described to sense several 
nucleic acid intermediates generated during the viral life cycle (Mogensen et al., 2010). APCs have 
played a significant role in inducing innate immune responses via TLR against HIV-1, however this study 
will focus on TLR7/8 and 9 inducing plasmacytoid dendritic cells, since they have been implicated on 
contributing to major sex differences in HIV-1 infection.  
 
 
Figure 1.7: Toll-like receptors (TLR) embedded on endosome that senses viral ssRNA, dsRNA and dsDNA. 
Signaling pathway showing activation of adaptor molecule MYD88 that recruits IRAK and TRAF 6 molecules 
which results in phosphorylation and activation of NFKB molecules causing induction of Type1 IFN-α and pro-
inflammatory cytokines (Gregersen and Behrens, 2006) 
 
1.7 Sex differences in HIV pathogenesis and IFNs anti-viral response 
Sex differences in HIV-1 disease progression have been reported previously (Moore et al., 2001). The sex 
differential outcomes of disease progression have been contradictory, initially HIV infected females were 
reported to live long following HIV seroconversion, they also had least chances of progressing to AIDS. 
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Moreover, one study found that women who were infected heterosexually had slow HIV progression rates  
(Jarrin et al., 2008). However, Mosha et al. (2013) showed similar rates of disease progression between 
females and males and found out that sex differential disease progression outcomes have changed over 
the years. Recently, intensive research has been done on determining differences in markers of disease 
advancement and the distinctive risk between opposite sex progressing to AIDS.  
Strong evidence show that females infected with HIV-1 elicit stronger immune responses and faster 
disease progression in comparison with men who have the same viral loads (Farzadegan et al., 1998). The 
mechanism underlying these sex differences is not completely understood. However, it has been reported 
in previous in vitro studies that sex differences in HIV-1 infection induced immune activation are 
associated with high production of IFN-α by plasmacytoid dendritic cells (pDCs) in response to TLR7/8 
from females (Meier et al., 2009, Chang et al., 2013). Although other cells, including macrophages, also 
secrete IFN-α under certain conditions, the IFN-α levels produced by these cell types is several folds 
lower than that produced by pDCs. TLR7, 8 and 9 play a central role in sensing viral pathogens such as 
HIV-1 and induce secretion of IFN-α by pDCs, thus contributing to higher levels of immune activation in 
women compared to men (Farzadegan et al., 1998, Seillet et al., 2012, Torcia et al., 2012). 
HIV-1 infected women express significantly increased levels of some markers of immune activation in 
comparison to men (Gianella et al., 2016). This induction of markers of immune activation has been 
associated with sex hormones (Meier et al., 2009). Sex hormones have great impact on immune cells 
functionality, as determined by transcriptome analysis done on PBMCs isolated from both men and 
women. Sex steroids carry out their function through binding to specific receptors which has been 
expressed by myeloid and plasmacytoid dendritic cells, receptors like estrogen (ER), androgen receptor 
(AR) and progesterone receptor (PR). Therefore, this indicates that these hormone receptors have 
significant immunoregulatory functions on APCs (Fischer et al., 2015).  
High production of IFN-α is beneficial for women during acute infection since it results in low viral loads 
and high CD4 counts (Figure 1.8) (Addo and Altfeld, 2014). Although beneficial during acute infection, 
the immunomodulatory effect of IFN-α during chronic infection results in persistent chronic inflammation 
in women compared to men (Addo and Altfeld, 2014). Type I IFNs display numerous biological effects. 
They have a strong antiviral action but  can also cause detrimental action in the host by inducing chronic 
persistent immune activation in HIV-1 infection (Hosmalin and Lebon, 2006). They activate proliferation 
of natural killer (NK) cells and T cells and nitric oxide synthesis by macrophages, and  enhance lysis of 
infected cells by cytotoxic T cells or T helper type 1 cells (Hosmalin and Lebon, 2006). IFN-α in 
particular, plays a central role in activation and maturation of DCs to generate effective APCs with 
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increased ability to stimulate CD4+ and CD8+ T cells; high levels of IFN-α are strong predictors of HIV-1 
clinical progression (Meier et al., 2009). However, immunological effects of IFN-α during immune 
reconstitution on ART has not been investigated between sexes. 
 
 
Figure 1.8: IFN-α stimulated gene (ISG) induction following stimulation of plasmacytoid dendritic cells (pDCs) by 
HIV through Toll-like receptor 7 (TLR-7) between women and men thus resulting in upregulated levels of IFN-α 
(Addo and Altfeld, 2014).  
 
 
1.8 Sex differences in response to antiretroviral therapy 
South Africa implemented its first national treatment programme in 2004, and currently has the largest 
ART programme in the world with an estimated 3.5 million people on ART in March 2016 (report, 
2015/16).  South Africa became the first country in sub-Saharan Africa to completely approve the use of 
pre-exposure prophylaxis (PrEP) in HIV-1 negative people who are at risk of contracting the virus in 
December 2015 (AVERT, 2017). Many people will be on ART, since SA has implemented universal treat 
and test initiative, whereby people living with HIV or testing positive will be initiated on ART 
immediately after diagnosis, regardless of their CD4 counts as of September 2016 (AVERT, 2017). 
Despite this intervention of reducing AIDS related mortality and morbidity, the ART programme is 
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limited by several factors such as co-infection with other pathogens, treatment adherence, drug toxicity, 
adverse effects and drug resistance.  
According to Moore et al. (2003), HIV-1 drug therapy study has shown that equivalent access to care, 
precise administration and adherence to ART has no significant sex based differences in treatment 
response. A study showed comparable proportion of females and males attained undetectable viral loads 
after 6 months of ART (Meditz et al., 2011). In contrast, previous studies proposed that side effects of 
ART and clinical deterioration could differ by gender. In these studies, the outcomes were mostly seen in 
first and second generation antiretroviral therapy, where women experienced skin rashes, mitochondrial 
toxicity, gastrointestinal intolerance and lipodystrophy (Ofotokun and Pomeroy, 2003). These toxicities 
and side effects may lead to non-compliance from women on ART. Furthermore, clinical studies reported 
sex-based effects such as nausea in women using Efavirenz compared to men using the same drug 
(Hodder et al., 2012). However, sex-based adverse effects and immunological response after initiation of 
ART remains unclear. 
1.8.1 Immune reconstitution after anti-retroviral therapy 
The introduction of antiretroviral therapy (ART) in Africa has made a significant contribution in 
minimizing AIDS associated deaths due of immune recovery as a result of decreased HIV-1 replication 
(El-Sadr et al., 2006). However, in some patients, ART can cause adverse events such as enormous 
activation of immune response that results in immune reconstitution inflammatory syndrome (IRIS), 
which is an immune restoration disease that is normally triggered by initiation of ART (Murdoch et al., 
2008, El-Sadr et al., 2006). The majority of IRIS cases develop within 3 months of ART initiation during 
early rapid immune recovery and it can also occur when a failing ART regimen is switched with an 
effective treatment or when ART is resumed after interruption (Meditz et al., 2011). The most common 
forms of IRIS are related to underlying opportunistic infections with mycobacteria, cryptococal infections 
or viruses. The utmost forms of IRIS manifestation can be either an inflammatory response that is caused 
by unmasking of previously untreated infection or the paradoxical clinical deterioration whereby immune 
cells target dead or dying organism in a patient that is on appropriate antimicrobial therapy (Dhasmana et 
al., 2008). 
No gold standard characteristics of IRIS exists; currently IRIS is defined as an exaggerated and atypical 
inflammatory reaction associated with a decrease in HIV RNA concentration from baseline or an increase 
in CD4+ T cell counts from baseline in recipients of effective ART (French et al., 2004). Although most 
cases of IRIS occur in patients with low CD4+ T cell counts and high viral load levels prior to 
antiretroviral therapy, IRIS can occur at any CD4+ T cell count (Müller et al., 2010). Most studies have 
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reported an increased risk of IRIS in patients initiating ART who have advanced disease (Müller et al., 
2010, Zaidi et al., 2012). The proportion of patients that initiate ART and develop IRIS is not well known, 
but it is estimated to vary between 7 to 50%. Two South African prospective studies showed that 10% of 
patients starting ART developed all-cause IRIS and TB-IRIS developed in 23% of patients who had 
started TB therapy prior to ART (Murdoch et al., 2008, Haddow et al., 2009). 
1.9 Study rationale 
Several studies have enlightened us about the disease progression and the existing sex based differential 
outcomes between males and females. Antiretroviral therapy (ART) has played a significant role in 
controlling disease progression and transmission by reducing viral load as the only available lifesaving 
intervention for people living with HIV-1 infection. However ART has adverse effects on some patients, 
such as aberrant immune response leading to immune reconstitution inflammatory syndrome (IRIS) 
(Wilson and Sereti, 2013). Additionally, women are more susceptible to antiretroviral drug-induced 
adverse effects (Fischer et al., 2015). 
There are different underlying biological mechanisms leading to pronounced sex differences in response 
to HIV-1 infection and immune reconstitution under ART; these include genetic, immunological and 
hormonal determinants of immunity. Antigen presenting cells especially pDCs of the innate immune 
system have been implicated in contributing to biased immune shift seen between males and females. 
Data have shown that women infected with HIV-1 have higher TLR7 mediated IFN-α responses of pDCs 
that results in higher persistent chronic inflammation in females (Meier et al., 2009). However, very little 
is known about ART in reversing this immune defect and whether these differ between males and 
females. 
Sex differences have been investigated in vaccine development and studies show that women elicit robust 
immune responses compared to men (Klein et al., 2010). With the unsuccessful development of an 
effective HIV vaccine so far, dissecting the biological factors resulting in sex differences in HIV-1 
infection is essential to minimize adverse effects on people who are put on ART. This study enabled us to 
study the consequences of ART on immune reconstitution between sexes through the assessment of 
antigen presenting cells and pro-inflammatory cytokines in males and females following initiation of 
ART. 
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1.10 Aims of the study 
Study Aim 1:  
Assessment of sex-based differences by analysis of pro-inflammatory function of antigen-presenting cells 
(APC) in peripheral blood mononuclear cells (PBMCs) in women compared to men. 
Objectives 
❖ To assess immune activation during immune restoration under ART by assessing the phenotype and 
quantification of cytokines (IFN-α, IL-12, MIP-1β and TNF-α) produced by APCs (monocytes, 
mDCs and pDCs) using multicolor flow cytometry in women and men. 
❖ To determine inflammatory response by evaluating the frequency of activated T cells and monocyte 
subsets (CD14++CD16-, CD14++CD16+ and CD14+CD16++) in women and men before and after ART 
initiation using phenotypic stain.  
Hypothesis 1:  
We hypothesized that females will have higher levels of immune activation during immune reconstitution 
under ART that is due to rapid reconstitution of TLR7 based IFN-α production by pDCs in response to 
HIV compared to men. 
 
Study Aim 2:  
Assessment of pro-inflammatory cytokines in plasma using Luminex in women and men before and after 
initiation of ART. 
Objective 
❖ To determine systemic cytokine profiles, the following cytokines:  IFN-ɣ, IL-1β, IL-4, IL-5, IL-6, 
IL-7, IL-8, IL-10, IL-12, IFN-α, TNF-α, MIP-1β, GM-CSF, IL-12p40, IL-12p70 and IP-10 were 
measured in plasma from males and females using multiplex analysis (Luminex). 
Hypothesis 2 
We hypothesized that sex differential levels of immune activation would result in increased systemic 
cytokine production in females due to rapid immune reconstitution. 
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CHAPTER 2: METHODOLOGY 
2.1 Study Ethics consideration 
This study was approved by the Biomedical Research Ethics committee (BREC) of the University of 
KwaZulu-Natal (Ref number: BE148/15), informed consent was obtained from all participants. Ethical 
approval was obtained for the studies (Ref number: NK-E118/06; SK- E028/99 and AI- E036/06) from 
Edendale, Sinikithemba and Acute infection study. 
2.2 Study Participants 
Samples from 24 black South African treatment experienced participants enrolled in HPP studies; 
Edendale, Sinikithemba and Acute infection, which were recruited from Pietermaritzburg and Durban 
areas in KwaZulu-Natal, were used for this study. Of these 24 patients, 11 were males and 13 were 
females, which were sampled before ART initiation and following ART. Clinical characteristics of the 
study participants are described below. In brief, peripheral blood mononuclear cells (PBMCs) and plasma 
samples were obtained and analyzed at one time-point before initiation of ART (at baseline) and at two 
time-points within 8 months of ART start date. All the patients enrolled had a CD4+ T cell count of 
between 50 and 400 cells/mm3 at initial sampling. A significant difference was observed in CD4+ T cell 
counts (p<0.02) and viral load (p<0.04) at baseline between males and females (Appendix II).  
2.3 Viral load and CD4 count measurement 
Absolute CD4 counts were measured by TruCount technology using flow cytometry. Plasma viral loads 
were measured using Roche Amplicor version 1.5 test and NucliSens HIV-1 QT assays, as previously 
described (Koofhethile et al., 2016). The sensitivity of the both tests was 50 RNA copies/ml. 
2.4 Isolation and preparation of cryo-preserved PBMCs 
The Ficoll density gradient method was employed for the isolation of PBMCs from whole blood samples 
as previously described (Thobakgale et al., 2007). This process entails overlaying of blood onto Ficoll 
Histopaque (Sigma), which can then be centrifuged to obtain gradients of specified densities. After 
centrifugation, cells with greater density such as granulocytes and erythrocytes sediment at the bottom of 
the tube while PBMCs form a layer in the middle. Cells of interest are then harvested, counted and 
cryopreserved in liquid nitrogen at (-210 ˚C -346 ˚F) for long term storage until further use. 
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2.5 Thawing of cryo-preserved cells 
Cryopreserved PBMCs were used in our assays. Cells were thawed before use, this process entails 
holding the cell vial into a water bath at 37 ˚C until small amount of frozen pellet remained. The outside 
of the cryo-tube was swabbed with 70% ethanol before it was quickly transferred to a 15ml tube, followed 
by addition of 10ml of pre-warmed R0 medium (RPMI 1640) drop wise to the cells and centrifuged for 7 
minutes, 1500 rpm at 25 ˚C. After centrifugation, the supernatant was discarded to ensure that all the 
freezing solution containing dimethyl sulfoxide (DMSO) was removed to minimize cell toxicity. The cell 
pellet was re-suspended in warm R10 medium (500 ml RPMI 1640 (Sigma) supplemented with 50 ml 
heat inactivated & filter sterilized fetal calf serum, 5 ml L-glutamine, 5 ml Penstrep fungizone (100x) & 5 
ml HEPES) and centrifuged again for 7min, 1500 rpm at 25 ˚C. The cell pellet was then re-suspended in 
10 ml of R10 medium followed by cell counting. Cells were counted manually by performing a 1 in 10 
dilution of cells in trypan blue; 10 µl of the mix was then pipetted on the haemocytometer counting slide 
(HYCOR Biomedical, USA) and the cells were counted using Olympus CH20 microscope (Olympus 
Optical, Japan). The cells were then reconstituted to a desired concentration of 1.5 million/ml in R10 
before use in subsequent in vitro stimulation assays or phenotypic characterization using multiparameter 
flow cytometry assays.  
2.6 Flow cytometry assays 
BD LSR Fortessa was used in this study for phenotypic and intracellular cytokine staining assays. Flow 
cytometry is made of 3 basic components, which include: fluidic system, optics (lasers) and electronics 
system. It consists of 5 lasers, however only 4 were used for our experiments; (blue laser 488nm, yellow 
green laser 560nm, red laser 640 and violet laser 405) and can be used to detect up to 18 colours 
simultaneously. Flow cytometry is defined as the simultaneous analysis of multiple physical 
characteristics of a single cell, as the cell flows in the stream of fluid through a laser. This technique 
involves the use of labeled cell components with the antibody fluorochromes, which are excited by the 
laser to emit light and fluorescence collected by lenses and filters to appropriate detectors while collecting 
data which is stored in the computer. Generated light scatter distinguishes between cells by size and 
internal complexity, whereas light emitted from fluorescently labeled antibodies identifies a wide array of 
cell surface and cytoplasmic antigens.  
2.6.1 Phenotypic assessment of antigen presenting cells and quantification of T cell activation 
For phenotypic assays, 250 to 500 hundred thousand PBMCs were stained with viability dye (1µl/ml) 
(Invivogen) and surface makers using anti-CD3 BV650, anti-CD123 BV421, anti-HLADR PE-CF594, 
anti-CD19 BV510, anti-CD56 BV510, anti-CD11c PE Cy5, anti-CD14 APC-Cy7, anti-CD38 PE, anti- 
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CD4 APC, anti-CD69 PerCP/Cy5.5 (all from Biolegend), anti-CD86 PE Cy7, anti-CD8 FITC and anti-
CD16 BV786 (from BD Biosciences) at optimal staining concentrations, (Table 1). The cells were 
incubated in the dark for 20min at room temperature (RT), and then washed with 2%PBS-FCS to block 
non-specific binding. Cells were fixed with medium A (Invitrogen) for 15 minutes at room temperature 
and then washed and resuspended in 120µl of PBS before flow cytometry acquisition.  Initial gating was 
on lymphocytes SSC-A versus FSC-A, followed by removal of doublets by forward scatter height (FSC-
H) versus forward scatter area (FSCA). Live/dead, B cells and NK cells were discriminated by the use of 
viability dye, CD19 and CD56 respectively; subsequently the CD3 negative (CD3-) and T cells population 
were gated on, followed by identification of CD8+ and CD4+ T cells, before activated CD8+ and CD4+ T 
cells were identified. From the CD3- population, monocytes subsets were gated on based on expression of 
CD14+ and CD16+ and specifically classified as (classical monocytes CD14++CD16-, intermediate 
monocytes CD14++CD16+ and non-classical monocytes CD14+CD16++). Gates were standardized using 
fluorescence minus one (FMO) controls. The stained cells were acquired on a LSR FORTESSA (BD 
Biosciences). Spectral overlap was corrected by suitable compensation and rainbow beads were employed 
to retain the consistency of the fluorescence intensity between experiments. A minimum of 100 000 to 
500 000 events were acquired for phenotypic assays. The gating strategy is shown in Figure 3.2. 
2.6.2 In vitro Stimulation of PBMCs with TLR ligands  
Antigen-presenting cells (APCs): monocytes, plasmacytoid dendritic cell (pDCs) and myeloid dendritic 
cells (mDCs) from PBMCs were analyzed for their ability to secrete cytokines in response to TLR 
stimulation (immune activation) using multiparametric flow cytometry (FORTESSA, BD Biosciences). 
For ICS assays, between 1.5x106 - 2x106 cells/ml PBMCs resuspended in R10 medium were used. The 
cells were rested for 2 hours before cell stimulation with the following conditions: TLR7/8-CL097, 
TLR4-LPS and TLR9-CpG from Invitrogen for 18h hrs. The cells were treated with a protein transport 
inhibitor Brefeldin A (BFA, Sigma) to assess intracellular cytokine production (Figure 2.1). CpG 
stimulant was prepared prior to stimulation, the stimulant was freshly prepared each time by adding 5.5ul 
of DOTAP transfection reagent (Roche) to 64µl of RPMI followed by incubation for 10 minutes at room 
temperature (RT). After incubation, 10µl of CpG and a further 27.5 µl of RPMI were mixed and 
incubated for 15 minutes at RT. Following CpG preparations, a total of 1.5 x 106 to 2 x106 of PBMCs per 
ml were stimulated with: 1µl/ml CL097 (Invivogen), 1µl/ml LPS (Invivogen) and 107 µl/ml 
CpG/DOTAP/RPMI mix in duplicate. Unstimulated cells with media alone were used as a control. BFA 
5µl/ml was added immediately to the tubes to inhibit release of cellular cytokine before incubating for 18 
hrs at 370C. 
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2.6.3 Analysis of cytokine production by multiparameter flow cytometry  
After 18hrs of incubation, BFA tubes were washed with PBS and centrifuged at 1500 rpm for 7 minutes 
at 25˚C. The supernatant was discarded followed by addition of viability dye (1µl/ml) (Invitrogen) and 
surface antibody master mix of: anti-CD3 BV650, anti-CD123 BV421, anti-CD19 BV510, anti-CD56 
BV510, anti-CD11c PE Cy5, anti-CD14 APC-Cy7, anti-CD38 PE, anti- CD4 APC, anti-HLA-DR PE-
CF594 (all from Biolegend) (Table 1) and incubated for 20 minutes at RT in the dark. While the 
incubation was taking place, the supernatant was collected from tubes without BFA for LUMINEX and 
the pellet was dissolved in 1ml Trizol (Life technologies) for PCR in each condition per time point; then 
all tubes were frozen down at -80˚C for downstream assays beyond the scope of this masters work. 
Once incubation was done in BFA tubes, cells were washed with 2%FBS/PBS and then fixed with 60µl 
Fix & Perm medium A (Invitrogen) for 15 minutes at RT, followed by washing with 2%FBS/PBS. Next, 
the cells were permeabilized using 60µl Fix & Perm medium B (Invitrogen) and stained intracellularly 
with anti-IFN-α PE, anti-TNF-α BV655, anti-IL-12 APC Cy7 and anti-MIP-1β FITC for 20 minutes at 
RT in the dark. The cells were washed and re-suspended in 140ul of PBS and analyzed on the 
FORTESSA (as mentioned above). Spectral overlap was corrected by suitable compensation and rainbow 
beads were employed to retain the consistency of the fluorescence intensity between experiments. A 
minimum range of 500 000 to 1 000 000 events were acquired for ICS assays. Cell populations of interest 
assayed for intracellular cytokines were defined as follows: monocytes (lineage-HLA-DR+CD11c-
CD123-CD14+), mDCs (lineage- HLADR+CD11c+CD123-CD14-) pDCs (lineage HLADR+CD11c-
CD123+CD14-). After successful acquisition the data files were saved to the BD FACS database then 
exported for further analysis with FlowJo version 10 (TreeStar, Inc.). The gating strategy is shown in 
(Figure 3.5, 3.7 and 3.9) and positive responses of (TNF-α, IFN-α, MIP-1β and IL-12) were reported after 
background subtraction. 
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Figure 2.1: Schematic overview of study design for phenotypic and ICS and staining illustrating samples size and 
panels. PBMC samples (n=24) from males (n=11) and females (n=13) were used in flow cytometry assays. 
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Table 2.1: Flow cytometry panels of the Phenotypic and ICS stains showing Fluorochromes used for 
analysis.  
Fluorochrome/ 
antibody 
Volume 
(1x)µl 
PANEL 1:       
Ex vivo   
volume 
(1x)µl Panel 2: ICS 
Per-CP-Cy5.5 2.5 CD69 
Surface  
markers 
  PE-Cy7 1 CD86  
   PE-Cy5 1 CD11c 
 
1 CD11c 
PE-CF594  1 HLA-DR  
 
1 HLA-DR  
APC-Cy7 1 CD14 
 
1 CD14 
BV421 1 CD123 
 
1 CD123 
BV786 1 CD16 
   BV650 2.5 CD3 Excluded 2.5 CD3 
BV510 1 Zombie aqua 
 
1 Zombie aqua 
 
2.5 CD19/56 
 
2.5 CD19/56 
FITC 1 CD8 
Intracellular 
Cytokines 2.5 MIP-1b 
PE 2 CD38 
 
1 IFN-α 
BV605  
   
1 TNF-α 
APC 1 CD4   1 IL-12 
 
2.7 Quantification of soluble cytokines in plasma using Luminex multiplex Assays  
Cytokines were measured in the plasma of samples with matched timepoints as the PBMCs. Luminex 
(Bio-Plex Pro assays) was used to simultaneously measure the levels of both anti and pro-inflammatory 
cytokines in 13 females and 8 males (only 8 male plasma samples were analysed due sample 
unavailability) before initiation of treatment, during 1-4 months and 5-8 months of treatment. The Bio-
Plex assay involves the use of microspheres which are 6.5 microns in size and fluorescently dyed to create 
100 distinct colours of bead. Two fluorescent dyes are used and the precise concentration of these 
fluorescent dyes creates 100 distinctly coloured bead sets. These beads are coated with a specific capture 
antibody, therefore this methodology has the potential to analyse 100 different analytes simultaneously.  
The technique of Luminex was invented from the traditional ELISA assay with the objective of 
quantifying low levels of different cytokines in one sample at the same time. This method involves the 
use of beads coated by the captured antibody. Coupled beads react with the analyte containing the 
biomarker of interest. After a series of washes to remove unbound protein, a labelled streptavidin 
detection biotinylated antibody which is specific for the captured antibody-cytokine complex is added to 
create sandwich complex. When the microspheres are passed through a laser which excites the fluorescent 
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dyes within the microsphere, the red laser classifies the bead according to what is being analysed 
(cytokine) and the green laser classifies the assay result according to the concentration of the analyte. The 
results are therefore quantified based on the fluorogenic emission. An overview of the technique is shown 
in (Appendix I). 
Plasma concentration of IFN-ɣ, IL-1α/β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, TNF-α, IL-
12p70, IL-17, G-CSF, GM-CSF, MCP-1, MIP-1β, IFN-α, IL-12 p(40) and IP-10 was determined in 
duplicate by (Bio-Plex Pro Human Cytokine 17-Plex Panel: 1x96-well, Bio-Plex Pro Human IFN-Alpha 2 
Assay: 1 x 96 well, Bio-Plex Pro Human IL-12 (p40) Assay: 1 x 96 well and Bio-Plex Pro Human IP-10 
Assay: 1 x 96 well) kits (Bio-Rad, Laboratories GmbH).  Luminex was done according to manufactures 
manual (BIO-RAD Laboratories, Inc). Plasma samples were prepared by making 1:4 dilutions, adding 1 
volume of sample to 3 volume of sample diluent, prior to assay setup. Standards and quality controls are 
included in each kit. The standards were reconstituted and serially diluted to 1:4 in an assay buffer. These 
standards were used as a reference for the quantification of the analytes.  
To briefly explain the method; wash buffer was added to the microtiter filter plate and placed on shaker at 
850±50 rpm for 10 minutes at room temperature. The detection beads (microspheres) were added to the 
wells and then washed to remove all unbound beads. The standards, assay buffer and samples were added 
and incubated for 30 min on shaker at 850±50 at RT. After incubation, the plate was washed again and 
the detection antibody was added. After 30 min of incubation at RT, the plate was washed again and the 
Streptavidin-PE conjugate was added, which acted as the reporter dye. This was incubated for 10 min on 
shaker at 850±50 rpm at RT. After incubation, plate was washed twice and the beads were resuspended in 
assay buffer, then the samples were quantified using Bio-Plex 200 system (Bio-Rad). Cytokines measured 
beneath the detection limit of the assay were given a value of the midpoint between zero and the detection 
limit value of the assay and they were included in the analysis. 
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2.8 Data and statistical analysis 
2.8.1 Intracellular cytokine staining and phenotypic stain 
The percentage of pDCs, mDCs and monocytes producing cytokines was determined by subsequent 
analysis using FlowJo software, version 10 (Treestar, Inc). FlowJo results were then exported to Graph 
Pad Prism, version 5 and analyzed by Two-way ANOVA for multiple comparisons across the time points 
for both groups. One Way ANOVA (Kruskal-Wallis test) and t- test (Mann-Whitney test) was used to 
asses cytokine production in different cell population between the groups. Results are expressed as 
means±SEM percentage of the cell population producing the following cytokines: TNF-α, IFN-α, MIP-1β 
and IL-12. A p value of ˂0.05 was considered significant.  
For phenotypic analysis, One way Anova (Kruskal-Wallis test) was used to calculate the frequency of 
monocytes subset and T cell activation across the time points in each group and t- test (Mann-Whitney 
test) was used to compare males and females at each time point. The correlation of activated T cell (CD8+ 
and CD4+) with viral load (copies/ml) in females and males at baseline was performed using Spearman’s 
non-parametric correlation. A smooth line was generated by linear regression. The Benferroni correction 
method was used to correct for multiple comparisons in all analyses. 
2.8.2 Cytokine profiling using Luminex 
Different methods of statistical analysis were used to determine if there were any sex differences between 
males and females producing pro- and anti-inflammatory cytokines before and after treatment initiation. 
The Bio-plex Manager software was used to acquire the data from the multiplex and singleplex assay 
plate. The data was analysed by Graph Pad Prism, version 5. Non-parametric t test (Mann-Whitney test) 
was used to determine the differences between males and females for each plasma cytokines in each time 
point. Kruskal-Wallis test was used to determine if there were any changes in each plasma cytokine level 
at baseline, during 1-4 months of treatment and 5-8 months of treatment in each group (males or females). 
The Spearman’s correlation test was used to determine if there was an association between plasma 
cytokine concentration (TNF-α, IFN-α and MIP-1β) and monocytes, mDCs and pDCs producing (TNF-α, 
IFN-α and MIP-1β) after stimulated with CL097, CpG and LPS. All the tests were two tailed and tests for 
significance were assessed at a 0.05 level of  significance. The Benferroni correction method was used to 
correct for multiple comparisons in all analyses. Twenty cytokines were tested but only 15 were detected 
and these were;  IFN-ɣ, IFN-α, IL-1β, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, TNF-α, IL-12p70, GM-
CSF, MIP-1β and IP-10.    
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2.8.2.1 Principal Component analysis of Luminex results 
Luminex data was analysed using multivariate techniques, specifically principal component analysis 
(PCA). Data was exported to an excel spread sheet and saved as CSV file. STATA was used to identify 
principal components which accounted for the majority of the variation in our dataset with the factor 
selection based on an eigenvalue ˃ 1.0 (see Appendix VII for the scree plot). PCA is a data reduction 
procedure that permits the major sources of variation in a multi-dimensional dataset to be analyzed 
without bias being introduced. PCA analysis was primarily performed to evaluate variation in the 
cytokine data set and to determine presence of clustering. Secondly, heat map was generated using 
components, to demonstrate contribution of each cytokines responsible for any of the clustering present 
(Appendix VIIII). Heat map was generated using the Miner Suite of bioinformatics software (CIMminer 
clustered image map Institute, from Genomics and Bioinformatics group, NIH). The Mann-Whitney U 
test was used to compare differences in cytokine production in each PC score between females and males 
infected with HIV-1. All the tests were two tailed and assessed at a 0.05 level of significance.  
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CHAPTER 3: RESULTS 
3.3 The clinical characteristics results of participants  
A total of 11 males and 13 females subjects were recruited from the Sinikithemba, Acute infection and 
Endendale studies from Pietermaritzburg and Durban areas in KwaZulu-Natal were used in the assays. 
The subjects were analyzed at baseline (before treatment), during 1-4 months of treatment and 5-8 months 
of treatment. Assays were done in matched time points on plasma and PBMCs samples. The clinical 
characteristics of study participants at baseline were as follows: median age of 31 years (IQR, 27-38 
years) for females and a median of 39 years (IQR, 32-51 years) for males. The median CD4+ T cell count 
for females was 179 cells/mm3 (IQR, 107-271 cells/mm3) and a median of 297 cells/mm3 (IQR, 203-353 
cells/mm3) for males. The median viral load for females was 79 167 RNA copies/ml (IQR, 15 750-131 
152 copies/ml) and 188 500 RNA copies/ml (IQR, 83 000-750 000 copes/ml) for males. The viral load 
significantly decreased in both males (p=0.001) and females (p˂0.0001) upon initiation of antiretroviral 
treatment (1-4 months of treatment). Furthermore, the levels of viremia markedly decreased at 5-8 months 
of treatment compared to baseline between males (p˂0.0001) and females (p˂0.01). However, most 
women achieved full viral suppression during the study period, whereas a much smaller percentage of the 
men achieved this during the study period. Reconstitution (restoration) of CD4+ T cells was minimal in 
males and significantly higher in females (p=0.02: Figure 3.1). Furthermore, several females had 
clinically defined AIDS (CD4<200) at the start of the study, while only one of the male participants had a 
CD4<200 and a significant difference was observed in viral load (p<0.04) at baseline, with males 
showing high levels of viremia compared to females (Appendix II).  
3.2 Characterization of activated CD8 and CD4 T cells and monocytes subsets 
Immune activation was first measured by assessing CD8+ and CD4+ T cells. CD8+ and CD4+ T cell 
activation was evaluated by co-expression of human leukocytes antigen (HLA)-DR+ and CD38+ 
phenotypic (activation) markers. Therefore, T cell activation was characterized by measuring changes in 
the frequency of CD8+HLA-DR+CD38+ and CD4+HLA-DR+CD38+ at baseline and following ART 
initiation in males (n=11) and females (n=10), (see gating strategy: Figure 3.2). There were no significant 
differences observed in both CD8+ and CD4+ activated T cells as determined by the frequency of HLA-
DR+ and CD38+ co-expression between males and females at all time-points measured (Figure 3.3 A + 
B). We next determined if there was an association between viral loads and activated T cells as previously 
shown by other studies (Meier et al., 2009, Scully et al., 2016). We observed a positive correlation of HIV 
viremia with both CD8+ (r=0.72, p=0.02) and CD4+ (r=0.66, p=0.04) activated T cells in females at 
baseline (Figure 3.3 C & D). In contrast, no correlation with viral load was observed in CD8+ (r=0.0173, 
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p=0.52) and CD4+ (r=0.18, p=0.61) T cells of males co-expressing HLA-DR+ and CD38+ (Figure 3.3 C 
and D).  
We next evaluated the innate immune response by assessing the inflammatory status of monocytes in 
males and females since previous reports have indicated that different subsets of monocytes, in particular 
the intermediate (defined as CD14++CD16+) and the non-classical (defined as CD14+CD16++) monocytes 
are contributors to inflammation in HIV-1 infection (Campbell et al., 2014, McCausland et al., 2015). We 
found significant differences in the proportion of classical monocytes (defined as CD14++CD16-) between 
males and females at baseline (p=0.03) where females showed a higher frequency of this subset compared 
to males (Figure 3.4 A). However, no significant differences were seen between males and females during 
the treatment phase (Figure 3.4 A). Similarly, no significant differences were observed in the frequency of 
intermediate and non-classical monocytes between males and females at baseline (before treatment), 
during 1-4 (TP02) and 5-8 months (TP03) of treatment (Figure 3.4 B & C). Taken together, these data 
reveal a possible inflammatory status and immune activation in females that is not observed in males. 
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Figure 3.1: Levels of HIV viremia (A-B) and CD4+ T cell counts (C-D) at baseline, 1-4 and 5-8 months of 
antiretroviral treatment in females (n=13) and males (n=11). Each color and shape represents time point. Data 
presented as Mean with SEM.  
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Figure 3.2: Gating strategy showing activated CD8+, CD4+ T cells and monocytes subsets. Identification of total 
monocytes from peripheral blood mononuclear cells was assessed following exclusion of doublets, dead cells, 
CD56+ and CD19+ expressing cells. Monocyte subsets were gated from the CD3-HLA-DR+ plot and identified based 
on the expression of CD14 and CD16 (left side). Three Monocytes subsets were identified as: Classical 
(CD14++CD16-), intermediate (CD14++CD16+) and non-classical or inflammatory monocyte (CD14+CD16++). 
Activated CD8+ and CD4+ were from the CD3+ population and defined by CD8+CD38+HLA-DR+ and 
CD4+CD38+HLA-DR+. The HLA-DR and CD38 fluorescence minus one (FMO’s) were used as a control. All the T 
cell plots were gated according to the (FMO’s) plot. The flow plots showing data for one representative female 
patient at time point (TP02) 1-4 months of treatment. 
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Figure 3.3: CD8+ and CD4+ T cell activation in males and females. The frequencies of CD8+HLADR+CD38+ (A) 
and CD4+HLADR+CD38+ (B) between males (n=11) and females (n=10) at baseline and during 1-4 and 5-8 months 
of post ART.  t- test (Mann-Whitney test) was used to compare groups at each time point and One way Anova 
(Kruskal-Wallis test) was used to calculate frequency across the time points in each group. The correlation of 
activated T cell (CD8+ and CD4+) with viral load (copies/ml) (C and D respectively) in females and males at 
baseline was performed using Spearman’s nonparametric correlation. A smooth line was generated by linear 
regression. 
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Figure 3.4: Representative plots showing percentage of monocytes subsets: (A) Classical monocytes, (B) 
intermediate monocytes and (C) non-classical monocytes between males (n=11) and females (n=10) at baseline, 
during 1-4 and 5-8 months of treatment. Median values and interquartile range are shown. t- test (Mann-Whitney 
test) was used to compare groups at each time point and one way Anova (Kruskal-Wallis test) was used to calculate 
frequency across the time points in each group. 
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3.4 Measurement of TLR responsiveness in females and males by ICS 
We next investigated the pro-inflammatory function of the following antigen presenting cells (monocytes, 
mDCs and pDCs) from cryopreserved PBMCs of study participants at baseline and following ART 
initiation to determine their polyfunctionality since these cells have been implicated in induction of excess 
immune activation in HIV-infected patients (Hosmalin and Lebon, 2006). Monocytes were characterized 
based on their relative expression of (HLA-DR+CD14+CD11c-CD123-; Figure 3.5). No significant 
differences were seen in the levels of the following cytokines (TNF-α, IFN-α, MIP-1β and IL-12) 
measured on monocytes following stimulation with CL097 (TLR7/8), CpG (TLR9) and LPS (TLR4) 
between males and females before ART and after ART initiation (Figure 3.6 A-D). The same observation 
was made in mDCs (defined as HLA-DR+CD14-CD11c+CD123-; Figure 3.7), indicating no significant 
differences in the levels of (IFN-α, TNF-α and IL-12) production between males and females (Figure 3.8 
A, B and D). However, the levels of MIP-1β-produced by mDCs in response to TLR9 ligand (CpG) were 
higher at 5-8 months of treatment in females compared to males (p= 0.01) and a trend towards higher 
MIP-1β production was also noted in females at 5-8 months post ART compared to baseline (Figure 3.8 
C).    
We next assessed pDCs defined as HLA-DR+CD14-CD11c-CD123+ (Figure 3.9). In contrast to the above, 
we observed sex differences with females demonstrating a higher percentage of pDCs producing TNF-α 
in response to TLR9 ligand compared to males at 1-4 and 5-8 months of treatment (p= 0.001: Figure 3.10) 
but not at baseline. In addition, females had greatly increased levels of TNF-α producing pDCs following 
TLR9 stimulation during 5-8 months of treatment compared to baseline (p= 0.004: Figure 3.6 A). 
Although there was a high induction in TNF-α production in response to TLR7/8 ligand (CL097), no 
significant differences were noted between males and females before treatment and after treatment 
initiation, similarly for LPS responses (Figure 3.10 A). Regarding IFN-α production by pDCs, females 
produced higher levels of IFN-α than males in response to TLR9 after 5-8 months of treatment (p=0.001) 
and also there was evidence of reconstitution of IFN-α responses on treatment compared to baseline on 
pDCs following TLR7/8 (CL097) and TLR9 (CPG) Figure 3.10 B). However, no differences were 
observed in IFN-α responses between males and females at baseline. 
No sex differences were seen in levels of MIP-1β produced by pDCs in response to TLR4 and TLR7/8 
ligands before and post ART (Figure 3.10 C). However, females had significantly higher levels of MIP-1β 
produced by pDCs in response to CpG ligand (TLR9) in comparison to males during 1-4 months of 
treatment (p=0.001) and no significant sex differences were observed at the subsequent time-point (TP03) 
at 5-8 months of treatment (Figure 3.10 C). In contrast to the above, only minimal IL-12 responses were 
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induced by the TLR-ligands and none showed any differences between males and females at all time-
points measured.  
Previous data have shown an inverse relationship between TNF-α production by monocytes and viral load 
(Scully et al., 2016). In the contrast to previous reports, our data showed no significant association 
between stimulus-specific cytokine (TNF-α) production from monocytes and plasma viral load at baseline 
in both males and females (Appendix III). Taken together, our data consistently demonstrate sex 
differences in cytokine specific responses across mDCs and most evidently on pDCs (TNF-α, IFN-α & 
MIP-1β pDCs) following stimulation with CpG-TLR9 ligand during ART. Moreover, females produce 
robust immune responses, demonstrating reconstitution of immune responses in response to TLR9 ligand 
stimulation during treatment compared to baseline. 
 
 
Figure 3.5: A representative scheme showing the flow cytometry gating strategy used for the analysis of 
monocytes population (CD14) and cytokine production in PBMCs. Panel A: Lymphocytes were gated from the 
SSC-H/FSA-A gate, followed by exclusion of doublets, dead cells, CD56+, CD19+ and CD3+ expressing cells. 
HLADR+ cells were gated from the CD3- cells. Panel B: monocytes population was obtained from the HLA-DR+ 
cells. Panel C: representative plot of cytokine production by monocytes, showing unstimulated and one stimulation 
with CL097 (TLR7/8). 
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Figure 3.6: Sex differences in cytokine production by monocytes. The above plots shows percentage of (IFN-α, 
TNF-α, IL-12 and MIP-1β) after background (unstimulated) subtraction  produced by monocytes following 18hrs of 
stimulation with CL097 (TLR7/8), CpG (TLR9) and LPS (TLR4) ligands at baseline, during 1-4 and 5-8 months of 
treatment between males (n=11) and females (n=13). Two-way ANOVA was used to calculate percentage of 
cytokines across the time point between males and females and One way Anova (Kruskal wallis test) was used to 
compare time points in each group, followed by t- test (Mann-Whitney test) comparing groups in each time point. 
Data presented as mean±SEM. ND represent cytokines which were not detected. 
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Figure 3.7: A representative scheme showing the flow-cytometry gating strategy used for the analysis of 
mDCs population (CD11c) and cytokine production in PBMCs. Panel A: Lymphocytes were gated from the 
SSC-H/FSA-A gate, followed by exclusion of doublets, dead cells, CD56+, CD19+ and CD3+ expressing cells. 
HLADR+ cells were gated from the CD3- cells. Panel C: mDCs population was obtained from the CD123+ cells and 
mDCs were characterized by CD11c+CD123-. Panel D: representative plot of cytokine production by mDCs, 
showing unstimulated and one stimulated with CL097 (TLR7/8). 
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Figure 3.8: Sex differences in cytokine production by mDCs. The above plots shows percentage of cytokines 
(IFN-α, TNF-α, IL-12 and MIP-1β after background subtraction) produced by mDCs following 18hrs of stimulation 
with CL097 (TLR7/8), CpG (TLR9) and LPS (TLR4) ligands at baseline, during 1-4 and 5-8 months of treatment 
between males (n=11) and females (n=13). Two-way ANOVA was used to calculate percentage of cytokines across 
the time point between males and females and one way Anova (Kruskal wallis test) was used to compare time points 
in each group, followed by t- test (Mann-Whitney test) comparing groups in each time point. Data presented as 
mean±SEM. ND represent cytokines which were not detected. 
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Figure 3.9: A representative scheme showing the flow-cytometry gating strategy used for the analysis of pDCs 
population (CD123) and cytokine production in PBMCs. Panel A: Lymphocytes were gated from the SSC-
H/FSA-A gate, followed by exclusion of doublets, dead cells, CD56+,CD19+ and CD3+ expressing cells. HLA-DR+ 
cells were gated from the CD3- cells. Panel C: pDCs population was obtained from the CD123+ cells and pDCs were 
characterized by CD11c-CD123+. Panel D: representative plot of cytokine production by pDCs, showing example of 
unstimulated and one stimulated with CL097 (TLR7/8). 
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Figure 3.10: Sex differences in cytokine production by pDCs. The above plots shows percentage of cytokines 
(IFN-α, TNF-α, IL-12 and MIP-1β after background subtraction) produced by pDCs following 18hrs of stimulation 
with CL097 (TLR7/8), CpG (TLR9) and LPS (TLR4) ligands at baseline, during 1-4 and 5-8 months of treatment 
between males (n=11) and females (n=13). Two-way ANOVA was used to calculate percentage of cytokines across 
the time point between males and females and One way Anova (Kruskal-Wallis test) was used to compare time 
points in each group, followed by t- test (Mann-Whitney test) comparing groups in each time point. Data presented 
as mean±SEM. ND represent cytokines which were not detected. 
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3.5 Measurement of plasma cytokine profiles in females and males using Luminex 
In order to determine changes in systemic cytokine profiles before and after ART initiation, 15 cytokines 
profile were quantified: IFN-ɣ, IFN-α, IL-1β, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, TNF-α, IL-
12p70, GM-CSF, MIP-1β and IP-10 in males (n=8) and females (n=13) at baseline, during (1-4) and (5-8) 
months of antiretroviral treatment. No significant differences were observed between males and females 
in the levels of systemic cytokines at baseline (TP01) and during 1-4 months of ART (TP02) (Figure 3.11 
A and B). Similarly, no significant differences were seen in all the cytokines except IL-8 (p=0.03), which 
was increased in females compared to males at 5-8 months of ART (Figure 3.11 C).  
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Figure 3.11: Sex differences in systemic cytokine profile of plasma between males (n=8) and females (n=13). t- 
test (Mann-Whitney test) was used to compare groups in each cytokine. The data represent mean with SEM. ND 
represent cytokines that were not detected. Only 8 male plasma samples were analyzed due to samples 
unavailability.   
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3.5.1 Determining systemic cytokine profile in plasma using Luminex- Principal Component 
analysis-PCA (exploratory analysis) 
Three components were identified from the scree plot with an eigenvalue greater than 1.0 for each time 
point. The resulting PCA components were used to generate a heat map which determined the presence of 
clustering and contribution of each cytokine. These three components accounts for the most amount of 
variance. The heat map (appendix VIIII) shows the relative contribution of each cytokine to the respective 
component. Thirteen cytokines which include those implicated in a pro-inflammatory role together with 
anti-inflammatory role contributed positively to most variation seen in component 1 of treatment naive: 
IFN-ɣ, IFN-α, IL-1β, IL-4, IL-6, IL-10, IL-5, IL-7, IL-8, IL-13, IL-12p40, IFN-α, TNF-α, IL-12p70, GM-
CSF, MIP-1β and IP-10. Conversely, GM-SCF, IP-10 and MIP-1β contributed negatively. The same 
observation was made at component one during ART (appendix VIIII). However, no significant 
differences were noted between males and females in the cytokine expression profile.  
The scores for each observation on Principal Component (PC) 1 and (PC) 2 are shown in appendix VII.  
The scores were used to identify clustering, which would suggest a common underlying multivariate 
signal (in this case inflammatory status of plasma) existing for that observed in a particular cluster. An 
individual with a larger loading score on a PC in a particular direction contribute more heavily to the 
multivariate signal in that direction and therefore make a greater contribution to observations with high 
scores on that PC.  We suggest that PC1 represents some aspect of the pro-inflammatory state of 
individuals in contrast to the individuals loading negatively on this axis. PC 1 and 2 demonstrate 
clustering of females and males according to pro-inflammatory status during treatment naïve and PC1 
represents 66.1% of the variance. Additionally, females were separated into two groups with some 
showing pro-inflammatory status in plasma. However, no significant sex differences were observed 
between males and females (appendix VIII). PC1 accounted for 55% of variation during (1-4 months of 
treatment) while PC2 accounted for 14%. Both males and females showed positive and negative 
contribution to the PCs but no significant sex differences in the pro-inflammatory status in plasma was 
exhibited. Similarly, no significant differences were seen between males and females at 5-8 months of 
treatment, although they both showed a decrease in pro-inflammatory status in plasma. 
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CHAPTER 4: DISCUSSION AND FUTURE WORK 
Sex differences have been demonstrated in disease manifestation between males and females in the course 
of HIV-1 infection. The advent of ART can yield desirable results in lowering viral loads, however excess 
immune activation can still persist. This ensues as a consequence of different kinetics in the restoration 
arms of the immune system, remarkably faster restoration of pro-inflammatory innate and adaptive 
pathways in contrast to regulatory mechanisms. This study aimed to investigate sex based differences 
kinetics in a cohort of males and females with HIV-clade C infection from Durban, South Africa. We 
hypothesized that immune restoration following initiation of ART will have significant sex based 
differential outcomes in immune responses in this African cohort. 
Our study results indicated that there was a significant association between activated T cells (CD4+HLA-
DR+CD38+ & CD8+HLA-DR+CD38+) with HIV-1 viral load in treatment naive females but not in males. 
Secondly, females had a higher frequency of classical monocytes (defined by CD14++CD16-) than males 
at baseline. Evident sex differences in cytokine (TNF-α, IFN-α & MIP-1β) specific responses were higher 
in pDCs (and less so on mDCs) of females compared to males following stimulation with CpG-TLR9 
ligand. Furthermore, females demonstrated robust immune activation in response to TLR9 ligand 
stimulation during treatment compared to baseline. Finally, our data showed no sex differences in all 
cytokines measured except for IL-8 that was increased in females during ART. 
Although several studies have demonstrated major sex differences in immune activation between males 
and females in HIV-1 infection, sex based differences in immune restoration during ART remains elusive. 
To establish the adaptive immune activation characteristics of individuals in this study, T cell activation 
was evaluated between males and females prior to and during ART using HLA-DR and CD38 markers 
established to be independent predictive tools for HIV-1 disease progression in the absence of ART 
(Fahey et al., 1990, Liu et al., 1997, Giorgi et al., 1999). The frequency of CD4+HLA-DR+CD38+ and 
CD8+HLA-DR+CD38+ at baseline and after treatment were slightly higher in females compared to males, 
but the differences were not significant.  
The study results indicated that there was a significant association between activated T cells and HIV-1 
viral load in treatment naïve females but not in males. Our data were in contrast to previous reports that 
demonstrated an association in both males and females with HIV viremia before ART initiation, although 
in women it was significantly higher compared to men (Meier et al., 2009). This disparity could be due to 
the fact that viral load were not matched for both males and females in our study compared to the 
previous study where controllers and progressors were examined, the participants in our study were 
selected based on their CD4+ T cell counts. Viral suppression by ART is associated with reduction in T-
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cell activation (Sachdeva et al., 2010). Studies have established that the rate of T-cell turnover and the 
degree of generalized T-cell activation both decrease after initiation of ART, signifying that viral 
replication directly contributes to heightened levels of T-cell activation (Deeks et al., 2004). Previous 
reports have shown that immune activation during ART is driven by low-level HIV viremia and microbial 
translocation in the gut leading to increased LPS (Sachdeva et al., 2010). Studies demonstrated that 
timing of ART initiation is a crucial factor that influences immune activation with one prospective study 
showing that cART initiated during acute infection exhibited reduced immune activation to normal levels 
after 48 week of ART (Rajasuriar et al., 2013). However, we noted a positive correlation of activated 
CD8+ T cells and viremia even after 3 months of ART treatment in females (appendix III). These 
observations could indicate the existing sex differences seen in chronic HIV infection, where females 
show elevated immune response despite initiation of ART as compared to males. 
Monocytes can be subdivided into three subsets with distinct cytokine profiles and immune functions in 
HIV-1 infected patients (Ziegler-Heitbrock et al., 2010). Classical monocytes play a significant role in 
defending against microbial pathogens; intermediate monocytes are associated with antigen presentation 
whereas inflammatory and non-classical monocytes exhibit patrolling properties (Chen et al., 2017). In 
the present study, females exhibited higher levels of classical monocytes compared to males at time point 
TP01 (treatment naïve). No differences were seen in the other monocyte subsets. Moreover, elevated 
levels of classical monocytes were correlated with a decrease in CD4+ T cell counts only in females at 
baseline (appendix IV). Therefore, these data suggest that monocytes and their subsets might contribute to 
the sex bias seen in innate immune responses. 
The composition of intermediate and non-classical monocytes expressing CD16+ differs between 
individuals but higher in ART naïve in comparison to individuals on ART, indicating that these cells 
might contribute to disease pathogenesis (McCausland et al., 2015). However, the proportion of these 
cells in HIV infection and during immune reconstitution between males and females is poorly understood. 
Our data showed that the proportion of non-classical monocytes and intermediate monocytes did not 
differ between males and females before treatment and after treatment initiation, although they remained 
elevated and higher (˃5%) than levels normally seen in healthy controls (Han et al., 2009). A study 
conducted on healthy women and men showed sex differences in non-classical monocytes with females 
showing significantly higher levels of non-classical monocytes compared to males (Jiang et al., 2014). In 
contrast, Hearps et al. (2012) showed sex differences in CD16+ expressing monocytes, specifically 
showing that females have lower proportions of non-classical monocytes compared to males. However, 
our study differs from previous studies in several aspects, most notably these ex vivo studies generated 
data based on cross-sectional comparisons of healthy controls with HIV-infected patients prior to and on 
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ART, they also separate them according to age (Han et al., 2009, Hearps et al., 2012). Therefore, these are 
likely to cause variations due to different disease stages compared. 
Additionally, we evaluated changes in monocyte subsets after the initiation of ART. No significant 
differences were observed between treatment naive and treated individuals in intermediate and non-
classical monocytes in males and females. Similar to our result, Scully and colleagues found no 
significant differences in the distribution of these subsets between viremic and suppressed patients (Scully 
et al., 2016). However, several studies have demonstrated an increase in CD16+ expressing monocytes in 
treatment naïve compared to ART treated individuals (Hearps et al., 2012, Campbell et al., 2014). Hearps 
and colleagues showed that monocytes phenotype and function can be affected by age, as they showed an 
increase in the proportion of CD16+ monocytes (considered inflammatory as a result of high TNF-α 
production) in young viremic HIV-positive individuals compared to elderly (Hearps et al., 2012). The 
discrepancy seen above in relation to our study might be due to the use of small sample size in the present 
study and the lack of analyzing a broader age range with sufficient patient numbers. 
Interestingly, a previous study comparing inflammatory monocytes between treatment naïve vs 
individuals on 3 months of treatment in chronic and acute infection showed that early initiation of ART 
treatment in acute infection can normalize monocytes activation, unlike in patients with chronic infection 
(Burdo et al., 2011). This irreversible monocytes activation can have adverse effect in HIV-1 infected 
individuals such as insulin resistance and lipodystrophy (Burdo et al., 2011). Therefore, since South 
Africa has introduced new ART guidelines which stipulate that all HIV-1 infected people be given ART 
soon after diagnosis, this early intervention may likely reduce many detrimental effects associated with a 
lower CD4 T cell count threshold (AVERT, 2017). 
Antigen presenting cells of the innate immune system have been implicated in chronic production of IFNs 
which have been found to be significant in driving the immune activation and disease progression in HIV-
1 infection. Furthermore, it has been demonstrated that HIV-1 infected females show a stronger immune 
activation and faster disease progression compared with males exhibiting the same viral load (Meier et al., 
2009). Due to the existing immune activation in females compared to males, we hypothesized that 
females will have higher levels of immune activation during immune reconstitution under ART due to 
rapid reconstitution of TLR pathways. 
We assessed the consequences of HIV-1 infection and ART initiation on the ability of antigen-presenting 
cells to respond to TLR stimulation. Our data showed diminished production of all cytokines in 
monocytes even when it was stimulated with LPS, considered as the major stimulant for monocytes due 
to their high expression of LPS receptor TLR4 and its related signaling molecule CD14 (Hearps et al., 
43 
 
2012). Monocytes are also regarded as the primary producers of pro-inflammatory cytokines such as 
TNF-α and IL-6. The reason behind this dysfunctional monocytes population is not clear but we can 
speculate that this could be due to that monocytes were exhausted as a result of already existing pro-
inflammatory function during exposure to HIV in vivo. Nonetheless, our findings confirm the previous 
reports, which showed no sex differences in the percentage of TNF-α and IFN-α produced by monocytes 
at baseline during chronic HIV-1 infection (Berghöfer et al., 2006, Meier et al., 2009). 
In line with previous reports, our data showed no sex differences in the percentage of IFN-α, TNF-α and 
IL-12 production by mDCs after stimulation with CL097, CpG and LPS before and after ART initiation 
(Meier et al., 2009). However, the levels of MIP-1β-produced by mDCs in response to TLR9 ligand 
(CpG) were higher at 5-8 months of treatment in females compared to males and a trend towards higher 
MIP-1β production was also noted in females (only) during 5-8 months of ART compared to baseline. 
This increase in mDCs responses during treatment might be caused by rapid reconstitution of mDCs upon 
ART, thus causing immune activation.  
Surprisingly, no significant sex differences in the frequency of IFN-α-producing pDCs in response to 
TLR7/8 before and after treatment were detected although females had slightly higher levels of these 
cytokines compared to males. These results are in contrast to a previous report which showed that pDCs 
derived from women produced more IFN-α in response to TLR7/8 ligands than pDCs derived from men 
(Meier et al., 2009). This could be caused by limited number of patients studied here since the previous 
studies had bigger cohort (˃50 patients). Furthermore, these differences might be a result of confounding 
factors such as age and use of contraceptives. However, in vitro stimulation of DCs from HIV-1 infected 
individuals with TLRs ligands has shown mixed data, with some studies showing reduced levels of IFN-α 
production during chronic HIV-1 infection than healthy controls (Ferbas et al., 1995, Martinson et al., 
2007, Sachdeva et al., 2008). 
Sex hormones have potent regulatory effect on innate immune cells (Roved et al., 2016). Studies have 
shown that sex hormones abundance can modulate the ability of pDCs to produce IFN-α in response to 
TLR7/8, specifically showing that Progestin modulate pDCs function in vitro (Hughes et al., 2008).  
Seillet et al. (2012), precisely showed a trend towards a lower percentage of IFN-α produced by pDCs 
stimulated by TLR-7/8 in postmenopausal compared to premenopausal women. Additionally, another 
study demonstrated that female mice with (estrogen receptor) ERα knockout exhibited impaired capacity 
to produce IFN-α after stimulation TLR7 ligand (Griesbeck et al., 2015). Therefore, these findings 
suggest that female sex hormones could regulate the TLR-mediated responses of pDCs. 
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Although sex differences were not seen in the levels of pDCs producing IFN-α in our study in response to 
TLR7/8, we noted an increase in induction of TNF-α and IFN-α by females after ART initiation 
compared to baseline. These results differ from the previous report demonstrating a decrease in IFN-α 
levels during ART compared to ART naïve (Lehmann et al., 2014). Moreover, primate studies have 
provided a critical insight into potential mechanisms of immune activation in chronic HIV infection. They 
have demonstrated that sooty mangabeys which are natural host of SIV lack CD4 T cell activation and 
depletion in spite of high viremia and their pDCs produce less IFN-α in response to SIV. Conversely, 
pDCs from rhesus macaques which are similar to human pDCs produce high levels of IFN-α in response 
to HIV and SIV in the absence of treatment and show high levels of immune activation (Tilton et al., 
2006, Mandl et al., 2008). This suggests that type I IFN’s play a significant role in mediating HIV 
induced immune activation during suppressed viremia. 
Sex differences have been described in the responses of pDCs to HIV infection, however responses of 
these cells during ART remain to be elucidated. The study showed significant sex-based difference in the 
levels of TNF-α during 1-4 and 5-8 months of treatment. Moreover,  we showed that pDCs derived from 
women produce markedly more TNF-α in response to CpG than pDCs derived from men during ART. In 
contrast neither CL097 nor LPS induced significantly different levels of pDCs producing TNF-α in males 
and females, although it was slightly higher in females. Furthermore, it was observed that during 5-8 
months of ART, pDCs IFN-α response to CpG was higher in females compared to males. The results also  
showed that during treatment females had elevated levels of TLR responsiveness in comparison to males. 
Lastly, pro-inflammatory cytokines in plasma from females and males were assessed. Cytokine levels are 
indicative of the nature of the immune response for a certain individual (Van der Watt et al., 2014). No 
significant sex differences were observed between males and females in the levels of systemic cytokines 
at baseline during 1-4 and 5-8 months of ART except IL-8, which was significantly increased in females 
compared to males at 5-8 months of ART. A study done by (Pananghat et al., 2016) demonstrated that IL-
8 may serve as a potential prognostic marker in conjunction with CD4 counts to monitor disease 
progression and the efficacy of ART. IL-8 is also known as a mediator associated with systemic 
inflammation (Calza et al., 2017). The levels of IFN-ɣ, IP10, MIP-1β and TNF-α remained elevated even 
after 8 months of treatment between both males and females and may indicate a systemic inflammation in 
these patients that did not demonstrate a declined during ART. 
Additionally, Principal component analysis (PCA) was carried out to investigate inflammatory status of 
plasma between males and females at various time points. The heat map expression profile indicated that 
both pro-inflammatory and anti-inflammatory cytokines contributed to most of the variation seen, even 
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though it was not significantly different between males and females. Moreover, females generated two 
clusters in score plot (appendix VIII), both clusters were indicative of pro-inflammatory status of plasma, 
while the males only formed one cluster which did not show any inflammation signs. However, no 
significant sex differences were observed at all-time points (baseline, 1-4 months and 5-8 months of 
treatment). 
The increase in pro-inflammatory response in females as compared to males after initiation of ART seen 
in this study suggested that TLR-dependent response of pDCs in women might contribute to high levels 
of immune activation and enhanced risk of immune reconstitution inflammatory syndrome (IRIS). The 
pathophysiology of IRIS is not completely understood, however, it is believed that IRIS is caused by 
enhanced dysregulated immune response to disease-specific antigens which results in an overproduction 
of inflammatory mediators in patients who recently started ART before full reconstitution of their T cells 
(Stone et al., 2004, Lipman and Breen, 2006, Tilton et al., 2006, Scully et al., 2016). 
This study has several limitations related to the heterogeneous nature of our patient’s age, control group 
and ART. No control group (healthy individuals) were included, it was thus difficult to make conclusions 
with regards to intermediate and non-classical monocytes subsets since it is known that these populations 
are found in abundance in HIV-1 infection (McCausland et al., 2015). Furthermore, we could not get 
fresh specimens from the recently recruited volunteers to verify and compare the findings obtained from 
the cryopreserved PBMCs, since it is known that freezing may have a negative impact on the viability and 
functionality of the cells. The studied patients were not receiving the same antiretroviral therapy, 
therefore this difference could also be a confounding factor. We had no information on any hormonal 
contraceptive used, thus we cannot exclude the possibility that hormones may influence the parameters 
measured here. It should be noted that the range of CD4+ T cell count used to select the recruits was very 
broad thus resulting in several females having the clinically defined AIDS (CD4<200) at the start of the 
study while the males had a CD4>200. Therefore, the variation in disease stages between these two 
groups could introduce bias. Moreover, the observed sex differences might be driven by sex or may be 
driven by the variations in disease stage and response to ART between the two groups. Small sample size 
could also be a result of the trends mostly observed in this study, thus a larger sample size in this cohort 
of individuals will lead to more conclusive results on the role ART and immune reconstitution. 
Nonetheless, the study confirmed previous reports that T cell activation correlates positively with plasma 
HIV RNA levels but only in females, and showed that CpG and not CL097 induced most of pro- 
inflammatory cytokine responses in pDCs. The study identified major sex differences in the level of TNF-
α pDCs response to TLR9 ligand (CpG) in patients who are on ART. This enhanced immune activation in 
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women might increase the risk of IRIS. Taken together, these findings provide a basis for future studies 
with a larger cohort that may provide further insight of adapting the HIV-1 therapy regimen based on 
differences in disease progression in each sex. 
Future work can include: 
❖ Evaluation of the effect of sex hormones on plasmacytoid dendritic cells in HIV-1 infection during 
immune reconstitution by quantifying plasma progesterone and testestorone levels between 
pregnant, non-pregnant females and males using Liquid chromatograpy-mass spectrometry 
(LCMS), in order to determine if sex hormone can further mediate this immune response during 
ART.  
❖ Assessment of systemic cytokine profiles in cell culture supernatant following TLR stimulation in 
males, pregnant females and non-pregnant females using Luminex. 
❖ To verify and compare the findings obtained from cryopresrved PBMCs with fresh PBMCs from 
(Females Rising Through Education, Support and Health (FRESH) study) which are recently 
recruited volunteers that start treatment following HIV diagnosis. This will be important in order to 
determine if long term cryopreservation has dentrimental effects on antigen presenting cells.  
❖ Additionally, we would quantify the expression of several interferon-stimulated genes (ISGs) from 
the pellet which was stimulated with CpG, CL097, LPS and the unstimulated control in HIV-1 
infected males, pregnant and non-pregnant females (from FRESH study and cryopreserved 
samples) using qualitative real-time polymerase chain reaction (qRT-PCR), as previously described 
by (Singh et al., 2014). This technique is commonly used to detect RNA expression. It is used to 
qualitatively and quantitatively detect gene expression through creation of complementary DNA 
(cDNA) transcripts using fluorescent probes and these fluorescent probes allow RT-PCR to 
measure amplification as it occurs during the experiment. We aim to determine whether males or 
females would have high ISGs and if these are associated with HIV-1-induced type I IFNs. 
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 APPENDIX I: Overview of Luminex Methodology. 
 
Overview of Luminex Methodology (images taken from www.bioradiations.com). Color-coded capture beads are 
incubated with the sample (plasma), followed by incubations with detection antibodies and a reporter dye. The Bio-
Plex reader classifies the beads by color, and then quantifies the associated reporter signal intensity, which indicates 
the level of cytokine present. 
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APPENDIX II: Viral load and CD4 count of males and females at baseline. 
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Viral load and CD4 count of males (n=11) and females (n=13) at treatment naïve (baseline). Data is presented as 
median with interquartile range; t test (Mann-Whitney test) was used to calculate the p value. 
 
APPENDIX III: Age of males and females at baseline.  
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The data showing results of ages between males and females at baseline (before treatment). Data is presented as 
median with interquartile range, t test (Mann-Whitney test) was used to calculate the p value. 
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APPENDIX IV: The percentage of activated CD8+ T cells vs viral load in males and females during 8 
months of ART. 
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APPENDIX V: The percentage of classical monocytes correlated with CD4+ T cells count in males and 
females at baseline. 
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APPENDIX VI: Monocytes TNF-α production after LPS stimulation correlated with plasma. 
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TNF-α produced by Monocytes after LPS stimulation associated with viral load in males and females. Spearman 
rank correlation was done and straight line was generated using liner regression. 
 
 
APPENDIX VII: Results of the principal component analysis (only principal components used in our 
analysis are shown).  
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APPENDIX VIII: PCA analysis showing clustering of both males (in blue) and females (in red) at 
treatment naïve, 1-4 months of treatment and 5-8 months of treatment. 
 
 
 
Principal component analysis showing inflammatory clustering status of males and females in PC1 and PC2 at 
treatment naïve, 1-4 and 5-8 months of treatment. Statistical comparison between males and females was done using 
Student’s t test. 
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APPENDIX VIIII: The graph showing eigenvalues and component numbers of 15 variables.  
 
 
Only two principle components were selected for further analysis that have an eigenvalue of greater than 1, the 
successive components were left out since they account for smaller amount of total variation. Heat map comparing 
15 plasma cytokine expression profiles of males and females at baseline (B) and 2 TPs (C&D) after treatment. The 
heat map color scale corresponding to the relative expression of the cytokine relative to the minimum and maximum 
of all values is shown at the bottom. Blue indicating lowest levels (negative contribution), red and maroon/brown 
indicating highest levels (positive contribution) and black indicating median levels relative to expression cytokine. 
